- •Rituximab (RTX) is considered to be an efficient and safe treatment for neuromyelitis optica (NMO).
- •Capillary leak syndrome (CLS) can be secondary to some medications.
- •There are only two fatal complications in NMO patient treated with RTX reported.
- •One case of CLS in NMO patient after rituximab treatment is presented.
- •Relationship between RTX and CLS causation is suggested.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
- An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.Ther. Adv. Neurol. Disord. 2016; 9: 180-188
- Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.Arch. Neurol. 2008; 65: 1443-1448
- Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective.Crit. Care. 2012; 16: 231
- Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.Neurology. 2011; 76: 1310-1315
- Capillary leak syndrome: etiologies, pathophysiology, and management.Kidney Int. 2017;
Yardimci B., Kazancioglu R., 2016. Idiopathic systemic capillary leak syndrome: a case report. Iran Red Crescent Med J [Internet]. Feb 20 (cited 2017 May 7);18(2). Available from: 〈http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867362/〉.
☆All authors have read the manuscript and approved its submission. The manuscript is not under review at any other publication. All the authors confirm that have no conflict of interest.